IL-6/Th17 signaling is essential for the initiation of experimental autoimmune myocarditis, highlighting it as a potential therapeutic target for preventing myocardial inflammation.
Does not support IL-6/Th17 inhibition in established myocarditis; hypothesis-generating for prevention with human validation needed.
IL-6-mediated induction of Th17 cells is critical for the onset of EAM, but not for its progression. IL-6/Th17 signalling could be a promising therapeutic target for the prevention of myocardial inflammation.
No takes yet. Share an insight, caveat, or question.
Yamashita et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: